Unique microRNA profile in Dupuytren's contracture supports deregulation of Β-catenin pathway

Modern Pathology

Volumn 23, Issue 11, 2010, Pages 1544-1552

  Mosakhani, Neda ^a   Guled, Mohamed ^a   Lahti, Leo ^a,b   Borze, Ioana ^a   Forsman, Minna ^c   Pääkkönen, Virve ^c   Ryhänen, Jorma ^c   Knuutila, Sakari ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b AALTO UNIVERSITY   (Finland)

^c UNIVERSITY OF OULU   (Finland)

Author keywords

Dupytren's contracture; microarray; miRNA

Indexed keywords

BETA CATENIN; MICRORNA; MICRORNA 101; MICRORNA 130B; MICRORNA 29C; MICRORNA 30B; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; WNT5A PROTEIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DUPUYTREN CONTRACTURE; FEMALE; FIBROBLAST; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; HUMAN CELL; MALE; MOLECULAR DYNAMICS; PALMAR FASCIA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REGULATORY MECHANISM;

AGED; AGED, 80 AND OVER; BETA CATENIN; CASE-CONTROL STUDIES; CELLS, CULTURED; DUPUYTREN CONTRACTURE; FEMALE; FINLAND; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; HEREDITY; HUMANS; MALE; MICRORNAS; MIDDLE AGED; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 78049453572     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.146     Document Type: Article

References (46)

1. McFarlane RM. Dupuytren's disease. J Hand Surg Ther 1997;10:8-13.
2. Shaw Jr RB, Chong AK, Zhang A, et al. Dupuytren's disease: history, diagnosis, and treatment. Plast Re-constr Surg 2007;120:44e-54e.
3. Ross DC. Epidemiology of Dupuytren's disease. Hand Clin 1999;15:53-62, vi.
4. Renard E, Jacques D, Chammas M, et al. Increased prevalence of soft tissue hand lesions in type 1 and type 2 diabetes mellitus: various entities and associated significance. Diabete Metab 1994;20:513-521.
5. Pan D, Watson HK, Swigart C, et al. Microarray gene analysis and expression profiles of Dupuytren's con-tracture. Ann Plast Surg 2003;50:618-622.
6. Bayat A, Walter J, Lambe H, et al. Identification of a novel mitochondrial mutation in Dupuytren's disease using multiplex DHPLC. Plast Reconstr Surg 2005;115:134-141.
7. Hu FZ, Nystrom A, Ahmed A, et al. Mapping of an autosomal dominant gene for Dupuytren's contracture to chromosome 16q in a Swedish family. Clin Genet 2005;68:424-429.
8. Qian A, Meals RA, Rajfer J, et al. Comparison of gene expression profiles between Peyronie's disease and Dupuytren's contracture. Urology 2004;64:399-404.
9. Lee LC, Zhang AY, Chong AK, et al. Expression of a novel gene, MafB, in Dupuytren's disease. J Hand Surg Am 2006;31:211-218.
10. Forsman M, Paakkonen V, Tjaderhane L, et al. The expression of myoglobin and ROR2 protein in Dupuy-tren's disease. J Surg Res 2008;146:271-275.
11. Satish L, Laframboise WA, O'Gorman DB, et al. Identification of differentially expressed genes in fibroblasts derived from patients with Dupuytren's Contracture. BMC Med Genomics 2008;1:10.
12. Shih B, Wijeratne D, Armstrong DJ, et al. Identification of biomarkers in Dupuytren's disease by comparative analysis of fibroblasts versus tissue biopsies in disease-specific phenotypes. J Hand Surg Am 2009;34: 124-136.
13. Wurster-Hill DH, Brown F, Park JP, et al. Cytogenetic studies in Dupuytren contracture. Am J Hum Genet 1988;43:285-292.
14. Bonnici AV, Birjandi F, Spencer JD, et al. Chromosomal abnormalities in Dupuytren's contracture and carpal tunnel syndrome. J Hand Surg Br 1992;17:349-355.
15. Casalone R, Mazzola D, Meroni E, et al. Cytogenetic and interphase cytogenetic analyses reveal chromosome instability but no clonal trisomy 8 in Dupuytren contracture. Cancer Genet Cytogenet 1997;99:73-76.
16. Kaur S, Forsman M, Ryhanen J, et al. No gene copy number changes in Dupuytren's contracture by array comparative genomic hybridization. Cancer Genet Cytogenet 2008;183:6-8.
17. Kraljevic Pavelic S, Sedic M, Hock K, et al. An integrated proteomics approach for studying the molecular pathogenesis of Dupuytren's disease. J Pathol 2009;217:524-533.
18. Bartels CL, Tsongalis GJ. MicroRNAs: novel biomar-kers for human cancer. Clin Chem 2009;55:623-631.
19. Winter J, Jung S, Keller S, et al. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009;11:228-234.
20. Lu M, Zhang Q, Deng M, et al. An analysis of human microRNA and disease associations. PLoS One 2008;3:e3420.
21. Wang H, Ach RA, Curry B. Direct and sensitive miRNA profiling from low-input total RNA. RNA 2007;13: 151-159.
22. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci USA 2003; 100:9440-9445.
23. Fabbri M, Croce CM, Calin GA. MicroRNAs. Cancer J 2008;14:1-6.
24. Dave SA, Banducci DR, Graham III WP, et al. Differences in alpha smooth muscle actin expression between fibroblasts derived from Dupuytren's nodules or cords. Exp Mol Pathol 2001;71:147-155.
25. Moyer KE, Banducci DR, Graham III WP, et al. Dupuytren's disease: physiologic changes in nodule and cord fibroblasts through aging in vitro. Plast Reconstr Surg 2002;110:187-193; discussion 194-6.
26. Bowley E, O'Gorman DB, Gan BS. Beta-catenin signaling in fibroproliferative disease. J Surg Res 2007; 138:141-150.
27. Varallo VM, Gan BS, Seney S, et al. Beta-catenin expression in Dupuytren's disease: potential role for cell-matrix interactions in modulating beta-catenin levels in vivo and in vitro. Oncogene 2003;22: 3680-3684.
28. Moon RT, Kohn AD, De Ferrari GV, et al. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 2004;5:691-701.
29. Degreef I, De Smet L, Sciot R, et al. Beta-catenin overexpression in Dupuytren's disease is unrelated to disease recurrence. Clin Orthop Relat Res 2009; 467:838-845.
30. O'Gorman DB, Wu Y, Seney S, et al. Wnt expression is not correlated with beta-catenin dysregulation in Dupuy-tren's Disease. J Negat Results Biomed 2006;5:13.
31. Liu Y, Rubin B, Bodine PV, et al. Wnt5a induces homodimerization and activation of Ror2 receptor tyrosine kinase. J Cell Biochem 2008;105:497-502.
32. Merzdorf CS, Sive HL. The zic1 gene is an activator of Wnt signaling. Int J Dev Biol 2006;50:611-617.
33. Pourebrahim R, Van Dam K, Bauters M, et al. ZIC1 gene expression is controlled by DNA and histone methylation in mesenchymal proliferations. FEBS Lett 2007;581:5122-5126.
34. Degreef I, De Smet L, Sciot R, et al. Immunohisto-chemical evidence for Zic1 coexpression with beta-catenin in the myofibroblast of Dupuytren disease. Scand J Plast Reconstr Surg Hand Surg 2009;43: 36-40.
35. Cordova A, Tripoli M, Corradino B, et al. Dupuytren's contracture: an update of biomolecular aspects and therapeutic perspectives. J Hand Surg Br 2005;30: 557-562.
36. Al-Qattan MM. Factors in the pathogenesis of Dupuytren's contracture. J Hand Surg Am 2006;31: 1527-1534.
37. Cheon SS, Nadesan P, Poon R, et al. Growth factors regulate beta-catenin-mediated TCF-dependent tran-scriptional activation in fibroblasts during the prolif-erative phase of wound healing. Exp Cell Res 2004; 293:267-274.
38. Sato M. Upregulation of the Wnt/beta-catenin pathway induced by transforming growth factor-beta in hyper-trophic scars and keloids. Acta Derm Venereol 2006;86:300-307.
39. Alioto RJ, Rosier RN, Burton RI, et al. Comparative effects of growth factors on fibroblasts of Dupuytren's tissue and normal palmar fascia. J Hand Surg Am 1994;19:442-452.
40. Bayat A, Stanley JK, Watson JS, et al. Genetic susceptibility to Dupuytren's disease: transforming growth factor beta receptor (TGFbetaR) gene polymorphisms and Dupuytren's disease. Br J Plast Surg 2003;56:328-333.
41. Lucas G, Brichet A, Roquelaure Y, et al. Dupuytren's disease: personal factors and occupational exposure. Am J Ind Med 2008;51:9-15.
42. Brickley-Parsons D, Glimcher MJ, Smith RJ, et al. Biochemical changes in the collagen of the palmar fascia in patients with Dupuytren's disease. J Bone Joint Surg Am 1981;63:787-797.
43. McFarlane RM, McGrouther DA, Flint MH. Dupuytren's Disease. Churchill Livingstone: New York, NY, 1990.
44. Dias JJ, Braybrooke J. Dupuytren's contracture: an audit of the outcomes of surgery. J Hand Surg Br 2006;31:514-521.
45. Wilbrand S, Flodmark C, Ekbom A, et al. Activation markers of connective tissue in Dupuytren's contrac-ture: relation to postoperative outcome. Scand J Plast Reconstr Surg Hand Surg 2003;37:283-292.
46. Abe Y, Rokkaku T, Ofuchi S, et al. An objective method to evaluate the risk of recurrence and extension of Dupuytren's disease. J Hand Surg Br 2004;29:427-430.